FULL PAPER

Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study

[1]KATRIJN L M MICHIELSEN, MSc, [2]IGNACE VERGOTE, MD, PhD, [1]RAPHAËLA DRESEN, MD, PhD, [1]KATYA OP DE BEECK, MD, [1]RAGNA VANSLEMBROUCK, MD, [2,3]FRÉDÉRIC AMANT, MD, PhD, [2]KARIN LEUNEN, MD, PhD, [1]PHILIPPE MOERMAN, MD, PhD, [4]STEFFEN FIEUWS, PhD, [1]FREDERIK DE KEYZER, MSc and [1]VINCENT VANDECAVEYE, MD, PhD

[1]Department of Imaging and Pathology, University Hospitals Leuven, Leuven, Belgium
[2]Department of Obstetrics and Gynaecology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
[3]Belgium and Center Gynaecological Oncology Amsterdam (CGOA), Antoni van Leeuwenhoek, Amsterdam, Netherlands
[4]Department of Public Health and Primary Care, University Hospitals Leuven, Leuven, Belgium

Address correspondence to: Dr. Katrijn Laura Mathijs Michielsen
E-mail: katrijn.michielsen1986@gmail.com

Objective: To assess the clinical feasibility of whole-body diffusion-weighted MRI (WB-DWI/MRI) for diagnosis and prediction of complete tumour resection in patients with suspected recurrent ovarian cancer.

Methods: 51 females clinically suspected for ovarian cancer recurrence underwent 3-T WB-DWI/MRI in addition to contrast-enhanced CT. WB-DWI/MRI was assessed for detection of tumour recurrence, prediction of tumour extent and complete resection compared with CT. Tumour presence was confirmed by pathology obtained by surgery or biopsy, or by imaging follow-up.

Results: WB-DWI/MRI showed 94% accuracy for detecting ovarian cancer recurrence, compared with 78% for CT ($p = 0.008$). WB-DWI/MRI showed better sensitivity [% (95% confidence interval)] than CT for detecting involvement of surgically critical tumour sites including mesenteric root infiltration [92 (62–100) vs 31 (10–61)], small bowel [93 (64–100) vs 21 (6–51)], colon carcinomatosis [91 (57–100) vs 27 (7–61)] and unresectable distant metastases [90 (54–99) vs 20 (4–56)]. WB-DWI/MRI correctly predicted complete resection in 33 of 35 (94%) patients eligible for salvage surgery compared with 17 of 35 (49%) for CT ($p < 0.001$).

Conclusion: WB-DWI/MRI allowed better detection of ovarian cancer recurrence and better prediction of complete resection than CT.

Advances in knowledge: WB-DWI/MRI could assist in optimizing treatment planning for recurrent ovarian cancer, particularly by improving patient selection for salvage surgery, thus giving eligible patients the highest chance on prolonged survival and refraining patients who would not benefit from extensive surgery reducing related morbidity and mortality.

INTRODUCTION

Despite continuing improvement of treatment of patients with ovarian cancer, up to 85% of these females will develop tumour recurrence.[1–4] Although debulking surgery is well accepted for treatment of primary ovarian cancer, the surgical management of recurrent disease remains controversial due to lack of major supporting prospective data and lack of well-defined operability criteria that may predict complete resection. A recent multicentre trial (DESKTOP II) prospectively developed the "Arbeitsgemeinschaft Gynaekologische Onkologie" (AGO) score providing a clinical tool to select patients for salvage surgery.[5] Complete resection at primary surgery, good performance status and absence of ascites represented a likelihood of 76% for secondary debulking to no residual tumour.[5] However, eligibility for salvage surgery largely depends on accurate and timely detection of tumour recurrence and accurate description of total tumour extent. The role of CT and fluorine-18 fludeoxyglucose positron emission tomography (^{18}F-FDG-PET)/CT for the detection of recurrent ovarian cancer has been established. However, their value for predicting complete resection remains controversial because commonly disease load is underestimated.[5–7] Diffusion-weighted MRI (DWI) distinguishes itself from conventional MRI sequences by the ability to detect water molecule displacements at a cellular scale (in the order of 10–30 μm) allowing functional characterization of tissue microstructural properties. The signal intensity of lesions depends on the amount of impediment of the movement of water molecules. The more

water molecule movement is restricted in tissues (*e.g.* tumoural lesions), the brighter the lesions appear on heavily diffusion-weighted images ($b = 1000\,s\,mm^{-2}$), in contrast to the suppressed background tissue, ascites and blood vessels.[8] The combination of this high-contrast ratio, spatial resolution in the order of millimetres, robust performance and short imaging times allows DWI to depict small tumour deposits in large body volumes in a clinically time-efficient way. For primary ovarian cancer, studies with abdominal and whole-body DWI (WB-DWI/MRI) have indicated high sensitivity for detecting metastases allowing to predict incomplete resection.[9–11] The purpose of this study was to assess the clinical feasibility of WB-DWI/MRI for diagnosis of patients with suspected recurrent ovarian cancer and prediction of complete tumour resection.

METHODS AND MATERIALS

Patients

Between July 2011 and June 2013, patients clinically suspected for recurrent ovarian cancer were prospectively and consecutively enrolled. The local ethics committee approved this study, and all patients provided written informed consent. Inclusion criteria were (1) suspicion of recurrent ovarian cancer based on clinical symptoms (*e.g.* bloating, pelvic or abdominal pain; diarrhoea; or constipation), clinical examination (including gynaecological ultrasound) and/or increase of cancer antigen 125 (CA-125) and (2) complete resection and completion of all chemotherapy cycles during primary treatment. Patients with contraindications to MRI (*e.g.* pacemaker, claustrophobia, MRI incompatible devices or implants) were excluded. All patients underwent WB-DWI/MRI in addition to the clinical CT scan, and imaging data were read blinded to other imaging and clinical/biochemical results.

At the oncologic board, patients were first decided on their clinical eligibility for salvage surgery based on the presence or absence of medical comorbidities, complicated primary surgery with abscesses or fistulization preventing major surgery and the DESKTOP II criteria including primary R0 resection, good performance status, and the absence of ascites.[12] In these patients, operability was then decided on the imaging appearance of disease spread according to institutional surgical criteria, with disease spread compromising surgery consisting of distant unresectable metastases, carcinomatosis of the duodenum, stomach, pancreas, large vessels of the coeliac trunk and hepatoduodenal ligament, metastases behind the portal vein, diffuse serosal small bowel or colon carcinomatosis or deep tumoural involvement of the superior mesenteric artery and mesenteric root.[12]

In case of conflicting WB-DWI/MRI and CT findings for recurrence detection or operability assessment potentially compromising curative treatment correlative invasive or imaging diagnostic tests were performed prior to treatment decision (Figure 1).

CT scanning

Breath-hold contrast-enhanced CT (Sensation 16, Sensation 64, Definition Flash; Siemens Medical Systems, Erlangen, Germany) was obtained, 90 min after per-oral contrast ingestion [30 ml iodinated contrast agent (Telebrix® Gastro; Guerbet, Roissy CDG Cedex, France), $300\,mg\,ml^{-1}$, in 900-ml water], chest scan 17 s and abdomen scan 90 s after intravenous contrast injection [120-ml iodinated contrast agent (Visipaque™; GE Healthcare A.S., Oslo, Norway); $320\,mg\,ml^{-1}$]. The following parameters were used: pitch of $1.2\,s^{-1}$, rotation speed of 0.5 s, slice thickness of 5 mm, slice gap of 1 mm and collimation of

Figure 1. Flowchart describing the process of clinical decision making towards salvage surgery following the imaging results; any case of conflicting imaging results that would potentially defer eligible patients from possible salvage surgery was correlated by either surgical exploration, biopsy of the surgically critical suspect lesion or correlative imaging. WB-DWI/MRI, whole-body diffusion-weighted MRI; PET, positron emission tomography.

0.6 mm. The reference tube voltage was set at 120 kV, and the reference current was 200 mAs for the abdomen and 110 mAs for the thorax using automated care dose software.

Whole-body diffusion-weighted MRI scanning

3-T WB-DWI/MRI (Ingenia; Philips Healthcare, Best, Netherlands) was performed with parallel radiofrequency transmission and phased-array surface coils. Free-breathing WB-DWI/MRI was acquired in four imaging stations in the transverse plane at $b = 0$ and $1000 \, s \, mm^{-2}$, covering the head to pelvis using the following parameters: short tau inversion recovery prepulse for fat suppression with inversion time (TI) of 250 ms, b-values in three orthogonal directions of 0 and $1000 \, s \, mm^{-2}$ with automated calculation of apparent diffusion coefficient maps, parallel imaging factor of 2.5, repetition time (TR) of 8454 ms, echo time (TE) of 67 ms, slice thickness of 5 mm, intersection gap of 0.1 mm, field of view (FOV) of $420 \times 329 \, mm$, acquired voxel size of $4.57 \times 4.71 \, mm$ with a reconstructed voxel size of $2.19 \times 2.16 \, mm$. The number of signal averages was two for the thorax (with two averages for $b = 0$ and six for $1000 \, s \, mm^{-2}$) and one (with one average for $b = 0$ and three for $1000 \, s \, mm^{-2}$) for all other stations. The number of slices was 45 for the head and neck imaging station and 50 for the other imaging stations. Multiplanar reformatted axial, coronal and sagittal WB-DWI/MRI images were reconstructed from the transverse b1000 images and combined into a single stack of WB-DWI/MRI images with a slice thickness of 5 mm.

Coronal free-breathing single-shot turbo spin-echo T_2 weighted and breath-hold abdominal-pelvic and thoracic gadolinium-enhanced (Dotarem®; Guerbet, Roissy, France) three-dimensional T_1 weighted gradient-echo sequences were used as anatomical reference. Coronal single-shot turbo spin-echo T_2 weighted images were acquired in three imaging stations with parallel imaging factor of 2, TR/TE of 3000/87 ms, slice thickness of 6 mm, interslice gap of 0.6 mm, FOV of $375 \times 447 \, mm$, parallel imaging factor of 4 and 35 slices for all stations.

Three-dimensional T_1 weighted gradient-echo sequences of the pelvis and abdomen were acquired with parallel imaging factor of 2, TR/TE of 3.6/1.25–2.20 ms, slice thickness of 1.5 mm, 90 slices, FOV $375 \times 304 \, mm$, acquired voxel size of $1.49 \times 1.50 \, mm$ and reconstructed voxel size of $0.71 \times 0.71 \, mm$ with one signal average. Coronal abdominal mDIXON was acquired with identical imaging parameters except for a FOV of 400 and 352 slices. Finally, a 20-s breath-hold 3D spoiled gradient echo of the chest was acquired with identical parameters as the mDIXON sequences except for a TR/TE of 3.2/1.5 ms, 148 slices and reconstructed voxel size of 0.98×0.97.

Patients drank 1 l of pineapple juice 2 h before the WB-DWI/MRI and were administered an antispasmodic (butylhyoscine, 20 mg intravenously) to improve the assessment of the small bowel serosa. The total scanning time was 38 min.

CT image interpretation

An abdominal radiologist with 12 years of experience interpreted the CT images. Peritoneal metastases were recorded when there was nodular, infiltrative or confluent thickening and/or contrast enhancement over the peritoneal surfaces, omentum or mesentery. Involvement of the bowel serosa was recorded in case of bowel masses, thickening or contrast enhancement of the bowel wall.

Nodal metastases were characterized based on morphological features indicating necrosis and short-axis diameter (1-cm threshold for abdominal lymphadenopathies and 0.5-cm threshold for thoracic lymphadenopathies).[13] Pathologically enhancing masses in the liver, lung or pleura were recorded as distant metastases.[14]

Whole-body diffusion-weighted MRI image interpretation

An abdominal radiologist with 10 years of experience interpreted the WB-DWI/MRI combining the information of b1000 diffusion-weighted images and anatomical sequences. Peritoneal metastases were recorded when there was nodular, infiltrative or confluent b1000 hyperintensity and/or contrast enhancement over the peritoneal surfaces, omentum or mesentery. Involvement of the bowel serosa was recorded in case of b1000 and/or contrast-enhancing bowel masses, nodular or infiltrative thickening of the bowel wall.

Lymph nodes were qualitatively assessed based on shape and b1000 signal intensity; lymph nodes showing (heterogeneous) higher b1000 signal intensity than the surrounding lymph nodes were considered malignant.[9] Distant metastases were identified based on increased b1000 signal not attributable to physiologically impeded diffusion or T_2 shine through.[15]

Reference standard

Exploration during laparotomy or laparoscopy with pathology was the primary reference standard. In case of suspected distant or retroperitoneal nodal metastases critical toward salvage surgery, image-guided biopsy or fine-needle aspiration cytology was performed. If surgical or histopathological correlation was impossible, correlative ^{18}F-FDG-PET/CT and/or imaging follow-up with consecutive CT or MRI scans for at least 6 months was used as the reference standard. All imaging, surgical and pathological reports used identical disease site labelling to facilitate proper correlation. The following imaging criteria were applied as the reference standard in the absence of surgical or histopathological correlation: assessed lesions with fluorine-18 fludeoxyglucose uptake not attributable to physiological or inflammatory uptake at correlative ^{18}F-FDG-PET/CT, appearing significantly larger (≥20% increase) during follow-up or showing a significant decrease (≥30%) under chemotherapy were considered true positive. Lesions detected at imaging but negative at correlative ^{18}F-FDG-PET/CT or resolving without therapy were considered false positive. Sites described negative at imaging, showing negative correlative ^{18}F-FDG-PET/CT or follow-up were considered true negative. Lesions undetected at imaging but positive at correlative ^{18}F-FDG-PET/CT or showing significant increase (≥20%) during follow-up were considered false negative.

Data analyses

STATISTICA 9.1 software (Statsoft Inc., Tulsa, OK) was used with p-values <0.05 indicating statistical significance. CT and

Table 1. Patient demographics

Patient Information	n (%)
Median age (years)	63 (range, 33–84)
Initial FIGO stage	
Borderline	1 (2)
I	3 (6)
II	4 (8)
III	31 (61)
IV	7 (14)
Unknown	5 (10)
Histology	
Serous papillary adenocarcinoma	36 (71)
Adult granulosa cell tumour	5 (10)
Clear cell carcinoma	2 (4)
Serous cystadenocarcinoma	2 (4)
Endometrioid carcinoma	1 (2)
Sertoli–Leydig cell tumour	1 (2)
Borderline mucinous tumour	1 (2)
Dysgerminoma (immature teratoma)	1 (2)
Carcinosarcoma	1 (2)
Unknown	1 (2)
Primary treatment	
Primary debulking surgery	38 (75)
R0 resections[a]	38 (100)
Interval debulking surgery after neoadjuvant chemotherapy	13 (25)
R0 resections	12 (92)
Rest <1 cm	1 (8)
Diagnosis-to-recurrence interval (months)	
Median (min.-max.)	31 (range, 5–285)
Pre-operative CA-125	
>35 U ml^{-1}	29 (57)
<35 U ml^{-1}	19 (37)
Unknown	3 (6)
Ascites	
No ascites	43 (84)
Limited ascites	5 (10)
Moderate ascites	1 (2)
Severe ascites	2 (4)

CA-125, cancer antigen 125; FIGO, International Federation of Gynaecology and Obstetrics; R0, no residual tumour; max., maximum; min., minimum.
[a]R0 resection, complete resection.

WB-DWI/MRI were compared for detection of tumour recurrence per patient, for assessment of tumour extent in sites critical toward surgery, including according to institutional surgical criteria as mentioned above, and for assessment of operability, with the aim for resection to no residual tumour.[12] Descriptive statistical data for WB-DWI/MRI and CT (sensitivity and specificity with 95% binomial confidence intervals, Clopper-Pearson) were determined per patient and for surgically critical sites. Per-patient statistical differences between WB-DWI/MRI and CT for detection of recurrence and operability assessment were examined using two-tailed McNemar tests.

RESULTS
Patients
56 females were included. After excluding 5 patients without surgical correlation or follow-up, 51 patients were analysed (median age 63 years, range 33–84 years). For all patients, the initial International Federation of Gynaecology and Obstetrics stage, histology, primary treatment, diagnosis-to-recurrence interval and CA-125, and the presence of ascites at the time of suspected recurrence are summarized in Table 1.

Figure 1 summarizes the clinical and therapeutic management of patients and use of the standard reference. Ovarian cancer recurrence was confirmed in 48/51 (94%). In three patients, tumour recurrence was excluded (explorative laparotomy and tumour-free imaging follow-up during 1 year in two patients and tumour-free imaging follow-up during 1 year in one patient) (Figure 2).

In 13 patients, no attempt for surgery was performed: 1 patient presented with negative imaging findings, even on correlative ^{18}F-FDG-PET/CT but became progressive under imaging follow-up; 2 patients refused surgery, 5 patients were randomized in the DESKTOP III chemotherapy arm and 5 patients had poor performance status (Figure 2). Imaging follow-up was used for correlation of initial findings on WB-DWI/MRI and CT.

35 patients were considered eligible for surgery, based on clinical criteria alone. 17 of these 35 (49%) patients underwent salvage debulking surgery, with 15 reaching resection to no residual tumour and 2 being inoperable at laparotomy. 18 of these 35 patients (51%) were deferred from surgery, based on imaging assessment of disease load (Figure 2). The discordant cases between CT and WB-DWI/MRI (9/18, 50%) were assessed with laparoscopy for correlation of peritoneal disease in three patients, (endoscopic) ultrasound-guided biopsy or fine-needle aspiration cytology in four patients (one suprarenal, one left supraclavicular, one mediastinal lymphadenopathy and one pleural metastasis) and ^{18}F-FDG-PET/CT in two patients (one suprarenal and one mediastinal lymphadenopathy).

Detection of ovarian cancer recurrence
WB-DWI/MRI correctly identified 47/48 (98%) patients with confirmed tumour recurrence with 94% accuracy compared with 40/48 (83%) for CT showing 78% accuracy ($p = 0.008$) (Table 2). In the three patients negative for tumour recurrence, WB-DWI/MRI was false positive in two and CT in all three patients.

Figure 2. Clinical and therapeutic management of patients and use of standard reference. pt, patient; WB-DWI/MRI, whole-body diffusion-weighted MRI; CE, contrast enhanced.

Disease extent critical for surgery: whole-body diffusion-weighted MRI *vs* CT

Table 2 shows comparative sensitivity and specificity with 95% confidence interval of WB-DWI/MRI and CT for assessing disease extent critical for surgery following the institutional operability criteria.[12] WB-DWI/MRI showed higher sensitivity for detecting confluent or multifocal carcinomatosis of the mesenteric root, the small bowel and colon than CT (Figure 3). In addition, WB-DWI/MRI had higher sensitivity for detecting unresectable metastases than CT (Figure 4).

Prediction of complete resection: whole-body diffusion-weighted MRI *vs* CT

In the 35 patients clinically eligible for salvage surgery, WB-DWI/MRI correctly predicted operability in 33 of 35 (94%) patients *vs* 17 of 35 (49%) patients for CT ($p < 0.001$).

In 18 of 35 (51%) patients, WB-DWI/MRI predicted inability of complete resection. Findings of diffuse peritoneal disease and/or distant metastases were concordant with CT findings in 9 of 18 (50%) patients and confirmed during further follow-up under systemic treatment. In the other 9 of 18 (50%) patients, WB-DWI/MRI predicted inoperability in patients regarded as operable by CT findings (Figure 2). The inoperability was confirmed either by laparoscopy, image-guided biopsy or correlation with ^{18}F-FDG-PET/CT in all nine patients. Compared with CT, WB-DWI/MRI correctly detected diffuse intestinal serosal spread in three patients, suprarenal or supradiaphragmatic subcentimetric lymphadenopathies in five patients and pleural metastases in one patient.

In 17 of 35 (49%) patients, WB-DWI/MRI predicted complete resection. Complete resection was possible in 15 of 17 (88%) patients, whereas the disease extent was underestimated in 2 (12%) patients found inoperable at the start of salvage debulking

surgery. In comparison, CT only predicted complete resection in 8 of 17 (47%) patients, underestimated disease extent in the 2 (12%) patients found inoperable at the start of salvage debulking surgery and wrongly assigned 7 patients as unable to reach resection to no residual tumour (Figure 2).

DISCUSSION

In this prospective study, WB-DWI/MRI showed higher accuracy than CT for detection of recurrent ovarian cancer and enabled better prediction of operability with the aim for complete resection. The better prediction of operability by WB-DWI/MRI over CT was mainly attributable to the higher sensitivity for detection of multifocal or diffuse serosal intestinal disease spread, metastases around the central mesenteric vessels and unresectable distant metastases.

The diagnostic accuracy of 94% for identifying patients with recurrent ovarian cancer by WB-DWI/MRI in our study is similar with results of a recent publication where whole-body MRI with DWI sequence detected recurrence of gynaecological tumour in 23 of 25 (92%) included patients.[16] Previous studies investigating the feasibility of MRI for detection of ovarian cancer recurrence have yielded variable results with sensitivity ranging between 57% and 90% and specificity between 33% and 100%.[17] Using abdominal gadolinium-enhanced MRI alone, Low et al[18] found 90% sensitivity, 88% specificity and 89% accuracy for detecting recurrent or persistent ovarian cancer after cytoreductive surgery, even in patients with normal CA-125. Balestreri et al[19] found 84% sensitivity and 100% specificity using combined T_2 weighted and gadolinium-enhanced MRI for detecting recurrent ovarian cancer in patients with rising tumour marker and negative thoracoabdominal CT. However, contrary to our study, older reports and a meta-analysis found no significant differences when comparing MRI and CT for detecting

Table 2. Comparative sensitivity and specificity for detection of recurrent disease and disease extent according to operability criteria between CT and whole-body diffusion-weighted MRI (WB-DWI/MRI)

Disease location	Imaging technique	Sens. (%) TP/(TP + FN)	95% CI		Spec. (%) TN/(TN + FP)	95% CI	
			LL (%)	UL (%)		LL (%)	UL (%)
Detection of recurrent disease							
Detection of recurrence	WB-DWI/MRI	98 (47/48)	89	100	33 (1/3)	1	91
	CT	83 (40/48)	70	93	0 (0/3)	0	71
Peritoneal carcinomatosis							
Superior mesenteric artery involvement	WB-DWI/MRI	100 (2/2)	20	100	100 (49/49)	91	100
	CT	50 (1/2)	3	97	100 (49/49)	91	100
Diffuse infiltration of mesenteric root of the small bowel	WB-DWI/MRI	92 (12/13)	62	100	97 (37/38)	85	100
	CT	31 (4/13)	10	61	100 (38/38)	89	100
Diffuse and confluent carcinomatosis of the stomach	WB-DWI/MRI	100 (6/6)	52	100	100 (45/45)	90	100
	CT	50 (3/6)	14	86	96 (43/45)	84	99
Diffuse and confluent carcinomatosis of the small bowel	WB-DWI/MRI	93 (13/14)	64	100	95 (35/37)	80	99
	CT	21 (3/14)	6	51	95 (35/37)	80	99
Intrahepatic M+	WB-DWI/MRI	100 (1/1)	5	100	100 (50/50)	91	100
	CT	0 (0/1)	0	95	92 (46/50)	80	97
Infiltration of large vessels of lig. hepatoduodenale	WB-DWI/MRI	100 (6/6)	52	100	100 (45/45)	90	100
	CT	33 (2/6)	6	76	100 (45/45)	90	100
Metastases behind the porta hepatis	WB-DWI/MRI	100 (7/7)	56	100	98 (43/44)	86	100
	CT	29 (2/7)	5	70	98 (43/44)	86	100
Multifocal or confluent carcinomatosis of the colon	WB-DWI/MRI	91 (10/11)	57	100	98 (39/40)	85	100
	CT	27 (3/11)	7	61	100 (40/40)	89	100
Distant metastases							
Resectable inguinal lymph nodes	WB-DWI/MRI	100 (1/1)	5	100	98 (49/50)	88	100
	CT	100 (1/1)	5	100	96 (48/50)	85	99
Solitary resectable retrocrural or paracardial nodes	WB-DWI/MRI	100 (1/1)	5	100	100 (50/50)	91	100
	CT	100 (1/1)	5	100	98 (49/50)	88	100
Unresectable distant metastases	WB-DWI/MRI	90 (9/10)	54	99	100 (41/41)	89	100
	CT	20 (2/10)	4	56	98 (40/41)	86	100

95% CI, 95% binomial confidence interval (Clopper-Pearson); FN, false negative; FP, false positive; lig., ligamentum; LL, lower limit; Sens., sensitivity; Spec., specificity; TN, true negative; TP, true positive; UL, upper limit.

recurrent ovarian cancer.[17,20,21] Besides lower sample sizes, a number of included studies in the meta-analysis were performed using different MRI techniques that lacked breath-hold imaging, fat saturation for contrast-enhanced imaging and DWI sequences. Substantial advances in MRI technology enabling fast breath-hold fat-saturated gadolinium-enhanced imaging and particularly the addition of a (whole body) DWI sequence are factors that have substantially improved sensitivity for detection of peritoneal and lymph node metastases.[17,20–22] This probably explains the improved detection of tumour recurrence and higher accuracy of WB-DWI/MRI over CT in our study.

More than its ability for detecting tumour recurrence, WB-DWI/MRI outscored CT for prediction of complete resection. The better prediction of operability by WB-DWI/MRI over CT in our study is in line with a report in primary ovarian cancer where abdominal DWI/MRI allowed prediction of suboptimal surgery with 90% accuracy.[11] In our study, WB-DWI/MRI correctly predicted operability in 94% of patients clinically eligible for salvage surgery. The substantially better detection of disease sites critical for surgery—predominantly multifocal or diffuse serosal intestinal metastases, metastases around the central mesenteric vessels and unresectable distant metastases—was the main contributor to the better

Figure 3. A 68-year-old female with previously treated Stage IV serous papillary ovarian cancer shows increased serum cancer antigen 125. Whole-body diffusion-weighted MRI shows carcinomatosis of the stomach, small bowel and colon, and peritoneal metastases depicted as diffuse linear or nodular b1000 hyperintensity of the serosal surfaces (arrows) (a, b, e, f) in correlation to T_2 weighted imaging (c). CT was interpreted as negative (d, g, h). Lesion progression at imaging follow-up during 6 months confirmed peritoneal carcinomatosis.


performance for operability assessment by WB-DWI/MRI than CT in our study. By large, this is explained by the superior contrast resolution of DWI for depiction of peritoneal and nodal/distant metastases over CT, particularly in the absence of ascites, in the bowel mesentery and serosa or in subcentimetric lymph nodes.[9,22,23]

Previously, doubt was cast on the diagnostic capacity of stand-alone WB-DWI/MRI for detection of recurrent gynaecological tumour, presumably by the impeding effects of post-therapeutic fibrosis and tissue scarring.[16] However, radiological–pathological correlation in treated head and neck cancer has shown that the low cellular density and large interstitial space of fibrosis corresponded with low signal intensity on high *b*-value DWI images, whereas the hypercellularity and restricted interstitial space in tumour recurrence resulted in increased signal intensity in high *b*-value DWI images. As such, DWI allows to differentiate recurrent tumour from treatment-induced fibrosis or inflammation irrespective of anatomical or metabolical imaging findings.[24]

The ability for precise diagnosis of recurrent cancer by DWI was confirmed in two studies, evaluating DWI for assessment of recurrent pelvic cancer. Lambregts et al[25] found that the

Figure 4. A 71-year-old female with previous history of high-grade serous papillary ovarian carcinoma with increased serum cancer antigen 125. Whole-body diffusion-weighted MRI shows b1000 strongly hyperintense mediastinal lymph nodes suspect for lymphadenopathies (dashed arrows) (a, b, c), interpreted as negative at CT (d, e, f). Cytology after endoscopic fine-needle aspiration confirmed these nodal metastases.

addition of DWI to the conventional MRI protocol reduced the number of false positives by 20% and improved interobserver agreement, thereby improving radiologist confidence. In that study, all eight patients with equivocal CT findings in this study were correctly diagnosed by DWI/MRI suggesting superior sensitivity and specificity for DWI/MRI than CT. Kitajima et al[26] showed that DWI had significantly better sensitivity and accuracy relative to T_2 weighted MRI with equal performance as contrast-enhanced MRI in 62 patients with suspected intrapelvic recurrence of gynaecological cancers. Importantly, adding DWI allowed better detection of metastatic disease sites other than the suspected site of tumour recurrence, allowing better description of total disease extent which may be useful for surgical planning.

Accordingly, in our study, the better description of total disease extent and improved sensitivity for small tumoural deposits enabled WB-DWI/MRI to better identify patients with peritoneal disease spread, lymphadenopathies or distant metastases beyond surgical reach than CT and thus better identify patients who would not benefit from salvage surgery due to incomplete resection. Contrarily, the better differentiation of tumour recurrence from post-treatment tissue distortions, particularly mesenteric infiltration not attributable to tumour, enlarged reactive lymph nodes and liver lesions allowed WB-DWI/MRI to better predict complete resection than CT; the latter wrongly assigning seven patients as having peritoneal or distant lymphadenopathies/metastases beyond surgical reach.

Although optimal salvage debulking surgery may improve median survival, its success depends on early detection of recurrence and thorough patient selection.[27] In order to optimize patient selection, clinical predictive score models including the AGO score and the model of Tian have been validated to overcome current radiological limitations for predicting complete resection.[28] In the DESKTOP II study—validating the AGO score—half of the patients had far more pre-operative tumour load than predicted by imaging and one-quarter of the patient disease load was overestimated by imaging, whereas the AGO score correctly predicted complete resection in 76% of the patients.[5,29] However, as a drawback, the AGO score is currently not designed to predict inoperability in negatively scored patients.[5,29] In addition, while both models have high positive-predictive value for complete resection of 82% and 80.3%, respectively, they suffer from relatively high false-negative rates 68.5% and 55.6%, respectively.[28] It is currently unclear whether diagnostic laparoscopy could enhance the predictive value of both models, bearing in mind an associated morbidity rate of 1–5%.[28,30,31] The high accuracy of WB-DWI/MRI of 94% for predicting operability and ability to identify both patients with under- and overestimated disease load by CT suggests its potentially additional value to clinical predictive models for operability assessment in patients with recurrent ovarian cancer.

This study has some limitations. Firstly, direct surgical or pathological correlation was not available for all disease sites. However, laparoscopy or laparotomy in patients in whom surgery was not indicated was considered non-ethical, and meticulous imaging follow-up was used instead. As per study design, lesions considered critical for surgical planning were confirmed by biopsy or laparoscopy.

Secondly, the patient population with direct surgical correlation was relatively small. However, this is inherent to the design of a single-centre pilot study for which only a selected number of patients are eligible for salvage surgery. Therefore, the results of this study need to be validated in larger study populations.

Thirdly, we did not compare the results of WB-DWI/MRI with ^{18}F-FDG-PET/CT. Not all patients with suspected recurrent ovarian cancer receive routine clinical ^{18}F-FDG-PET/CT in our centre due to its reported relatively low performance to predict complete resection.[5] Nevertheless, future comparative studies are warranted to elucidate the potential synergistic value of microstructural and metabolic imaging, especially in the advent of the development of hybrid PET/MRI.[16]

Lastly, we did not assess interobserver agreement. However, a recent study showed good interobserver agreement using similar interpretation criteria.[9]

In conclusion, WB-DWI/MRI showed high accuracy, superior to CT, for detection of ovarian cancer recurrence and prediction of complete resection in patients with clinical symptoms or increase of tumour marker. WB-DWI/MRI particularly improved the non-invasive assessment of multifocal or diffuse serosal intestinal tumour spread, metastatic deposits around the central mesenteric vessels and unresectable distant metastases.

Our study suggests that WB-DWI/MRI could substantially improve clinical management and patient selection for salvage surgery pending validation in larger studies.

CONFLICTS OF INTEREST

REFERENCES

1. Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. *Int J Surg Oncol* 2012; **2012**: 613980. doi: http://dx.doi.org/10.1155/2012/613980

2. StatBite: ovarian cancer: risk of recurrence by stage of diagnosis. *J Natl Cancer Inst* 2009; **101**: 1234. doi: http://dx.doi.org/10.1093/jnci/djp308

3. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. *Cochrane Database Syst Rev* 2011: CD007565. doi: http://dx.doi.org/10.1002/14651858.CD007565.pub2

4. Classe JM, Jaffre I, Frenel JS, Bordes V, Dejode M, Dravet F, et al. Prognostic factors for patients treated for a recurrent FIGO stage III

ovarian cancer: a retrospective study of 108 cases. *Eur J Surg Oncol* 2011; **37**: 971–7. doi: http://dx.doi.org/10.1016/j.ejso.2011.08.138

5. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. *Int J Gynecol Cancer* 2011; **21**: 289–95. doi: http://dx.doi.org/10.1097/IGC.0b013e31820aaafd

6. Lenhard MS, Burges A, Johnson TR, Stieber P, Kumper C, Ditsch N, et al. PET-CT in recurrent ovarian cancer: impact on treatment planning. *Anticancer Res* 2008; **28**: 2303–8.

7. Dragosavac S, Derchain S, Caserta NM, DE Souza G. Staging recurrent ovarian cancer with (18)FDG PET/CT. *Oncol Lett* 2013; **5**: 593–7. doi: http://dx.doi.org/10.3892/ol.2012.1075

8. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. *AJR Am J Roentgenol* 2007; **188**: 1622–35. doi: http://dx.doi.org/10.2214/AJR.06.1403

9. Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. *Eur Radiol* 2014; **24**: 889–901. doi: http://dx.doi.org/10.1007/s00330-013-3083-8

10. Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. *Eur Radiol* 2008; **18**: 18–23. doi: http://dx.doi.org/10.1007/s00330-007-0732-9

11. Espada M, Garcia-Flores JR, Jimenez M, Alvarez-Moreno E, De Haro M, Gonzalez-Cortijo L, et al. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. *Eur Radiol* 2013; **23**: 2636–42. doi: http://dx.doi.org/10.1007/s00330-013-2837-7

12. Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? *Gynecol Oncol* 2013; **128**: 6–11. doi: http://dx.doi.org/10.1016/j.ygyno.2012.09.013

13. Kolev V, Mironov S, Mironov O, Ishill N, Moskowitz CS, Gardner GJ, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. *Int J Gynecol Cancer* 2010; **20**: 979–84. doi: http://dx.doi.org/10.1111/IGC.0b013e3181e833f5

14. Forstner R. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. *Eur Radiol* 2007; **17**: 3223–35. doi: http://dx.doi.org/10.1007/s00330-007-0736-5

15. Thomassin-Naggara I, Toussaint I, Perrot N, Rouzier R, Cuenod CA, Bazot M, et al. Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. *Radiology* 2011; **258**: 793–803. doi: http://dx.doi.org/10.1148/radiol.10100751

16. Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, et al. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone. *Invest Radiol* 2014; **49**: 808–15. doi: http://dx.doi.org/10.1097/RLI.0000000000000086

17. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. *Eur J Radiol* 2009; **71**: 164–74. doi: http://dx.doi.org/10.1016/j.ejrad.2008.02.019

18. Low RN, Duggan B, Barone RM, Saleh F, Song SY. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. *Radiology* 2005; **235**: 918–26. doi: http://dx.doi.org/10.1148/radiol.2353040447

19. Balestreri L, Bison L, Sorio R, Morra A, Campagnutta E, Morassut S. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. *Radiol Med* 2002; **104**: 426–36.

20. Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Köchli OR, Seifert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. *Eur Radiol* 2000; **10**: 761–7.

21. Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. *J Comput Assist Tomogr* 1993; **17**: 626–32. doi: http://dx.doi.org/10.1097/00004728-199307000-00021

22. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings–a feasibility study. *AJR Am J Roentgenol* 2009; **193**: 461–70. doi: http://dx.doi.org/10.2214/AJR.08.1753

23. Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases—current and emerging techniques. *Nat Rev Clin Oncol* 2010; **7**: 381–93. doi: http://dx.doi.org/10.1038/nrclinonc.2010.47

24. Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers P, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. *Int J Radiat Oncol Biol Phys* 2007; **67**: 960–71. doi: http://dx.doi.org/10.1016/j.ijrobp.2006.09.020

25. Lambregts DM, Cappendijk VC, Maas M, Beets GL, Beets-Tan RG. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. *Eur Radiol* 2011; **21**: 1250–8. doi: http://dx.doi.org/10.1007/s00330-010-2052-8

26. Kitajima K, Tanaka U, Ueno Y, Maeda T, Suenaga Y, Takahashi S, et al. Role of diffusion weighted imaging and contrast-enhanced MRI in the evaluation of intrapelvic recurrence of gynecological malignant tumor. *PLoS One* 2015; **10**: e0117411. doi: http://dx.doi.org/10.1371/journal.pone.0117411

27. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. *Ann Oncol* 2009; **20**: 286–93. doi: http://dx.doi.org/10.1093/annonc/mdn591

28. van de Laar R, Massuger LF, Van Gorp T, IntHout J, Zusterzeel PL, Kruitwagen RF. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. *Gynecol Oncol* 2015; **137**: 210–5. doi: http://dx.doi.org/10.1016/j.ygyno.2015.02.004

29. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. *Ann Surg Oncol* 2006; **13**: 1702–10. doi: http://dx.doi.org/10.1245/s10434-006-9058-0

30. van de Laar R, IntHout J, Van Gorp T, Verdonschot S, van Altena AM, Gerestein CG, et al. External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer. *Br J Cancer* 2014; **110**: 42–8. doi: http://dx.doi.org/10.1038/bjc.2013.717

31. Chi DS, Abu-Rustum NR, Sonoda Y, Awtrey C, Hummer A, Venkatraman ES, et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. *Am J Obstet Gynecol* 2004; **191**: 1138–45. doi: http://dx.doi.org/10.1016/j.ajog.2004.05.004